Table 2.
Description of cohorts retained after the systematic review and included in the meta-analysis.
| Study | Number of patients | Age (years) | Age of onset (years) | Men (%) | Bulbar form (%) | ALSFRS | BMI (kg/m2) | Vitamin D levels (ng/ml) | Relation vitamin D and ALS |
|---|---|---|---|---|---|---|---|---|---|
| Gennings et al. (34) | 302 | 63.2 | 56.2 ± 11.8 | 59 | NR | 37 | 26 | NR | Prognosis |
| Cortese et al. (38) | 71 | NR | NR | NR | NR | NR | NR | 11.0 (4.0–38.0) | Diagnosis Prognosis |
| Bretón et al. (35) | 213 | 61.9 ± 13.3 | BO 67.4 ± 12 SO 59.4 ± 13.2 |
57 | 31.5 | NR | 25.6 ± 4.2 | <20 | Prognosis (BO x SO) |
| Trojsi et al. (41)** | 50.000: 10 75.000: 12 100.000: 11 |
57.6 (11.69) 62.17 (10.05) 54 (14) |
56.5 (11.75) 61.17 (10.49) 53.27 (14.1) |
20 58 81 |
NR | 37.6 (6.32) 35.67 (7.83) 38.45 (6.86) |
25.35 (2.63) 26.48 (3.29) 23.73 (2.92) |
16.7 (6.9) 14.3 (6.5) 14.9 (7.6) |
Therapy |
| Camu et al. (13) | 74 | 66.8* | 64.3 | 70 | 31 | 0.92 (ASS)*** | NR | 21.2 | Prognosis |
| Karam et al. (33) | 37 | 55 | vitD 47.2 (37.3–61) no vitD 60 (47.4–63.3) |
57 | NR | vitD 29 (16.5–39) no vitD 29 (22–38) | NR | 22.3 (13.5–32) | Therapy |
| Libonati et al. (36) | 57 | 63.0 ± 9.9 | NR | 82.4 | NR | NR | NR | 18.8 ± 12.1 ng/dl | Diagnosis Prognosis Therapy |
| Elf et al. (37) | 24 | 58 ± 12 | 57.6* | 58.3 | NR | 31 | 25.6 (18.1–43.6) | 23.6 ± 10.4 | Diagnosis Prognosis |
| Yang et al. (16) | 100 | 56.3* | 53.5 (45–63) | 59 | 31 | 40 (36–43) | 22.3 (20.5–24.7) | 13.7 ± 8.9 | Prognosis |
| Paganoni et al. (40) | 106 | 58.0 ± 9.8 | 56.2 ± 9.1* | 58.5 | 26.4 | 33.2 ± 8.4 | 27.2 ± 5.2 | NR | Prognosis |
| Blasco et al. (15) | 125 | 65 (63–67) | 62.4* | 50.4 | 34.2 | 34.4 (33.0–35.7) | 24.2 (23.5–24.8) | 20.3 (19.8–22.4) | Prognosis |
| Crick et al. (39) | 11 | 64.5 ± 10.8 | NR | 63.6 | NR | NR | NR | 5.2 (6.37) | Diagnosis |
| Pageot et al. (14) | 127 | NR | NR | NR | NR | NR | NR | NR | Prognosis |
| % Data | 100 | 69.2 | 46.1 | 84.6 | 38.5 | 61.5 | 53.8 | 76.9 | |
| Average | 98.5 | 55.7 ± 8.5 | 57.9 ± 10.7 | 59.6 | 30.8 | 31.4 ± 5.9 | 25.2 ± 4.3 | 14.5 ± 8.8 |
Data reported as mean ± S.D, except for Gennings, Karam, Yang, and Blasco who presented data as median.
NR, not reported; BO, bulbar onset; SO, spinal onset.
*
As estimated from the age of the cohort and disease duration or from age at diagnosis and disease duration.
**
Vitamin D supplementation groups (IU/month).
***
ASS: ALSFRS severity score (mean points lost per month).